Savara Inc (SVRA NASDAQ) stock market data APIs
$5.3178
-0.24(-4.5%)
as of June 11, 2026
Try our APIs with
free plan!
Savara Inc Financial Data Overview
Price chart is built with
Anychart
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Langhorne, Pennsylvania.
Prev. Close
5.3178
Open
5.0777
High
5.3896
Low
4.9389
52 wk Range
1.98-7.005
Market Cap
1 077 M
Shares Outstanding
205 M
Revenue
1 000
EPS
0
Beta
0.269
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Savara Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Savara Inc data using free add-ons & libraries
Get Savara Inc Fundamental Data
Savara Inc Fundamental data includes:
- Net Revenue: 1 000
- EBITDA: -133 168 000
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-07
- EPS/Forecast: -0.1183
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Savara Inc News
New
These 10 small-cap U.S. healthcare companies carry the market's most expensive valuations
[Financial market sector Healthcare on blue finance background from graphs, charts. 3D render] Vladimir Zakharov A screen of U.S. healthcare stocks with market capitalizations between $300M and $2B ...
What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge
Superstring Capital Management cut its stake in UroGen Pharma Ltd. (NASDAQ:URGN), selling 330,983 shares in the first quarter in an estimated $6.64 million trade based on average quarterly pricing, ac...
What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge
Key Points Superstring Capital sold 330,983 shares of UroGen Pharma Ltd last quarter; the estimated transaction value was $6.64 million based on quarterly average pricing. The quarter-end position va...
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally
Superstring Capital Management disclosed a new position in Vir Biotechnology(NASDAQ:VIR), acquiring 730,548 shares in the first quarter. The estimated transaction value was $5.82 million based on quar...
Get Savara Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
